LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Datacolor® today announced CHROMACAL™, a first-of-its-kind color calibration system for microscopy. Preview available at the American Society for Cell Biology meeting, Dec. 14-17 in New Orleans, LA.
HACKENSACK, N.J.--(BUSINESS WIRE)--New data presented at the 2013 American Society of Hematology (ASH) Annual Meeting provides further insight into the complexity of the genomic landscape in high-risk diffuse large B-cell lymphoma.
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies reported results of cohort 3 in its Phase 1b/2a clinical study of SNS01-T at the 55th American Society of Hematology Annual Meeting in New Orleans.
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Oppenheimer 24th Annual Healthcare Conference in New York on Tuesday, December 10, 2013 at 9:10 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar. About NPS Pharmaceu
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today announced that it will host an Investor and Analyst Event for its research analysts and institutional investors on Friday, December 6 at 8:30 a.m. ET in New York City. Francois Nader, M.D., president and chief executive officer of NPS, will host the event along with other key members of NPS senior management. Expert medical leaders will also be featured speakers at the meeting. The meeting will primarily focus on
BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals reports third quarter 2013 financial results and provides business and product development update
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported today the completion of cohort 3 of its Phase 1b/2a clinical trial for its drug, SNS01-T, for the treatment of multiple myeloma and lymphoma. The Company has also received approval from its Data Review Committee to proceed to cohort 4, which is expected to require six evaluable patients. The Data Review Committee’s review of the results of cohort 3 concluded that SNS01-T was safe